Optimizing Endoscopic Assessment of Postoperative Crohn's Disease: A Scoping Review Authors: Sarianne G Bosch, Michiel T J Bak, Sun‐Ho Lee, Oddeke Van Ruler, Léon Maggiori, Johan Burisch, Jakob B Seidelin, Byong Duk Ye, Sang Hyoung Park, Mark S Silverberg, Matthieu Allez, Annemarie C DeVries, Nassim Hammoudi, the IMPACT consortium Published: 2026 ABSTRACT ABSTRACTBackgroundPostoperative endoscopic recurrence after ileocecal resection in Crohn's disease (CD) occurs frequently and typically precedes clinical and surgical relapse. Endoscopic scoring systems are central to postoperative management, yet their optimal use remains debated. The aim was to provide a summary and critical appraisal of established and novel endoscopic scoring systems used for recurrence in adult CD.MethodsA scoping review was conducted based on a systematic search in PubMed, EMBASE, and the Cochrane Library databases. Following qualitative synthesis, narrative reviews and studies involving pediatric or animal populations were excluded. Remaining evidence was integrated and critically appraised. The interpretation of findings was further refined through expert discussion within the IMPACT consortium.ResultsThe Rutgeerts score (RS) remains the most widely used index in clinical studies, but shows important limitations, including moderate interobserver reproducibility, limited differentiation between anastomotic and ileal lesions, and reduced applicability to modern anastomotic configurations. Modified and updated RS variants, as well as newer indices, emphasize lesion location and postoperative anatomy, and may improve prognostic stratification in selected cohorts. The choice of postoperative endoscopic index and the threshold used to define recurrence has major clinical implications. Heterogeneity in anatomic lesions considered, cutoffs for adapting treatments, and reproducibility limit the universal adoption of any single index.ConclusionEndoscopic indices remain essential for classification and standardization for postoperative disease recurrence in CD but should be interpreted together with their current level of validation. These findings highlight the need for further validation, harmonization of definitions, and refinement of postoperative endoscopic evaluation. Abbreviations Area Under Curve Crohn's Disease Crohn's Disease Activity Index Crohn's Disease Endoscopic Index of Severity Endoscopic ulcer Activity Score for Evaluating Crohn's Disease Endoscopic Postoperative Recurrence Ileo Cecal Resection International Multidisciplinary Postoperative Crohn's Disease Consortium Intestinal Ultra Sound modified RS Postoperative Recurrence PRISMA extension for Scoping Reviews Rutgeerts Score Simple Endoscopic Score—Crohn's Disease Background Despite the growing arsenal of immunosuppressive therapies, ileocecal resection (ICR) remains a common intervention for patients with Crohn's disease (CD) [1]. Endoscopic postoperative recurrence (ePOR) within the first year after surgery occurs frequently in approximately 50% of patients [2, 3]. ePOR is known to precede both clinical and surgical recurrence and its prevention is important to avoid poor long‐term outcomes [4, 5, 6]. To prevent ePOR, accurate identification of patients at high risk is of clinical importance. The ECCO‐IBD guidelines identify smoking at time of surgery, penetrating disease behavior, prior surgical resection, perianal disease, granulomas in the resection material, myenteric plexitis, and absence of postoperative prophylactic treatment as established clinical risk factors for postoperative recurrence (POR) [7]. In contrast, the American guidelines state active smoking at time of surgery, ≥ 2 prior surgeries for penetrating disease with or without perianal disease, or younger age < 30 years as clinical risk factors [8]. Evidence supporting risk factors remains inconsistent across studies, reflecting substantial heterogeneity in the literature [9, 10, 11, 12, 13]. Notably, the recent study from REMIND group identified prior exposure to biologic therapy as a risk factor for POR and a recent systematic review that included studies from 2000 onward, only found consistent evidence for active smoking at time of surgery and previous bowel resection [14, 15]. Especially since risk stratification is difficult, early reassessment of postoperative strategy is mandatory. Postoperative ileocolonoscopy within 6–12 months after surgery is considered the gold standard for detection of recurrence and guidance for therapeutic intensification [7, 8, 16]. A reliable and reproducible endoscopic scoring system is particularly important, as postoperative treatment strategies are directly influenced by endoscopic findings. Currently, the Rutgeerts score (RS) and its modified versions remain the most widely used indices for assessing ePOR in clinical practice and clinical trials, even though their prognostic value was never validated. Several modifications and alternative scoring systems have been recently developed in response to postoperative lesion heterogeneity, intra‐observer variability, and changes in surgical techniques and anastomotic configurations [2, 17, 18, 19]. In response to these clinical challenges and the uncertainties in the developing field of postoperative endoscopic scoring, this review aims to provide a summary and critical appraisal of established and novel endoscopic scoring systems used for assessing ePOR in CD and gives an expert‐based opinion on the optimal approach to postoperative endoscopic evaluation. Methods This review was conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA‐ScR) guidelines [20]. A review of the literature was performed in December 2025. PubMed, EMBASE, the Cochrane Library, and congress abstracts were searched for articles published in English. The detailed search strategy is provided in Appendix 1 and the PRISMA‐ScR checklist is provided in Appendix 2. The search resulted in 1046 studies eligible for screening. Studies that evaluated an endoscopic scoring system for POR in adult CD were included in a qualitative synthesis by two authors (NH and SB), with particular focus on studies describing the interobserver variability and predictive value for long‐term postoperative outcomes. Studies conducted in pediatric populations or animal models were excluded, as well as review articles. No restrictions were applied regarding publication date or study design. In addition, to minimize the risk of selection bias arising from the omission of relevant studies, articles not identified through the search were included following manual review by both authors. Findings were summarized narratively, highlighting areas of consistency and gaps in the existing literature, thereby providing an integrated overview of the current state of knowledge. Experts from the newly formed International Multidisciplinary Postoperative CD Consortium (IMPACT—bringing together international experts in postoperative CD) critically reviewed this draft to obtain this final version. Endoscopic Assessment of POR Is the Gold Standard The assessment of recurrence solely based on clinical symptoms is unreliable, as many studies consistently demonstrated a discordance between clinical and endoscopic recurrence rates [4, 5, 21]. Regueiro et al. reported for instance poor agreement between the Crohn's Disease Activity Index (CDAI) and concurrent endoscopic recurrence, defined as RS > i2 [21]. For this reason, an objective evaluation is important in the postoperative setting. The current gold standard for assessing POR is ileocolonoscopy between 6 and 12 months after surgery [7, 8]. This recommended timing was adopted after the POCER trial demonstrated that early treatment optimization based on a standard 6‐month ileocolonoscopy significantly improved long‐term recurrence outcomes, a finding that was later confirmed [5, 16, 22, 23]. However, the definition of long‐term recurrence remains inconsistent across studies, warranting clearer and standardized outcome definitions [24]. In this context, the present scoping review focuses specifically on the assessment and interpretation of early ePOR. The First Endoscopic Scores Developed: CDEIS And SES CD The Crohn's Disease Endoscopic Index of Severity (CDEIS) represents one of the earliest attempts to quantify endoscopic disease activity in CD. By evaluating deep and superficial ulcerations, the extent of surface involvement, and the presence of stenosis across five predefined bowel segments, the CDEIS provides a sensitive assessment of mucosal inflammation (Table 1) [25]. Developed and published in the late 1980s, the score demonstrated a strong correlation with the endoscopist's global assessment of lesion severity (r = 0.83) and was subsequently prospectively validated in a series of 113 colonoscopies (r = 0.81), establishing its validity. Owing to these methodological strengths, the CDEIS became the reference endoscopic scoring system for luminal CD in clinical trials and has long served as a benchmark in research settings [26]. However, no study specifically evaluating the prognosis of CDEIS in the postoperative setting has been published. TABLE 1An overview of postoperative endoscopic scores.StudyScoreLesionsAdvantagesDisadvantagesReproducibilityPrognostic performanceAnatomical considerationsPractical limitationsMary JY et al. Gut, 1989CDEIS Segment by segment: Deep ulcerations Superficial ulcerations Surface involved by disease Surface involved by ulcerations Stenosis (ulcerated or not) Exhaustive Validated in luminal CD Captures colonic disease activity Largely used in clinical trials Not specific to postoperative CD Good to excellent intra‐ and interobserver agreement in luminal CD Substantial intra‐ and interobserver agreement in the postoperative setting Less interobserver agreement for the anastomosis Unknown in the postoperative settingDoes not specifically address anastomotic areasComplex to calculateDaperno et al. Gastrointest Endosc, 2004SES‐CD Segment by segment: Size of ulcers Ulcerated surface Affected surface Presence of narrowing Exhaustive Validated in luminal CD Acceptable intra‐ and interobserver agreement in postoperative setting Captures colonic disease activity Largely used in clinical trials Not specific to postoperative CD Good to excellent intra‐ and interobserver agreement in luminal CD Substantial intra‐ and interobserver agreement in the postoperative setting Less interobserver agreement for the anastomosis Limited evidence, but predictive of postoperative clinical recurrence and performance comparable to Rutgeerts score in several studiesDoes not specifically address anastomotic areasComplex to calculateRutgeerts et al., Gastroenterology, 1990Rutgeerts Neo‐terminal ileum and anastomosis: i1 = Not more than five anastomotic aphthous lesions in the distal ileum i2 = More than five aphthous lesions with normal mucosa between the lesions, or skip areas of larger lesions or ulcers up to 1 cm confined to ileocecal anastomosis i3 = Diffuse aphthous ileitis with diffusely inflamed mucosa between the multiple aphthae i4 = Diffuse inflammation, with larger lesions: large ulcers, nodules/cobble and/or narrowing/stenosis Specific to postoperative CD anatomy Practical to use Widely used Not validated Does not separate lesion from the anastomosis and the ileum Does not capture colonic disease activity Moderate to substantial interobserver agreement Less interobserver reliability especially when differentiating 5 aphthous ulcers, with normal intervening mucosa in between, in the neo‐terminal ileum (with or without anastomotic lesions) i3 = diffuse aphthous ileitis with diffusely inflamed mucosa i4 = large ulcers with diffuse mucosal inflammation or nodules or stenosis in the neo‐terminal ileum Specific to postoperative CD Separates lesions from the anastomosis and the ileum, potentially improving prognostic accuracy Not validated Does not capture colonic disease activity Substantial interobserver variability Moderate interobserver agreement for cutoff point ≥i2a Good to excellent intraobserver agreement Correlates with postoperative outcomes, including clinical and surgical recurrence Improved prognostic value compared to original Rutgeerts, with distinguishing anastomotic from ileal lesions Designed only on end‐to‐end configuration Separates lesions from the anastomosis and the ileum Requires experience in distinguishment of anastomosis Rivière et al., Clinical Gastroenterology and Hepatology, 2022 Updated Rutgeerts Neo‐terminal ileum and anastomosis: i0: No lesions in the neo‐terminal ileum, anastomotic line, ileal inlet, or ileal body i1: < 5 aphthous lesions in the neo‐terminal ileum, ileal inlet, or ileal body with normal mucosa in between i2a: Lesions confined to the ileocecal anastomotic line with or without < 5 aphthous lesions in the neo‐terminal ileum, ileal inlet, or ileal body with normal mucosa in between i2b: ≥ 5 aphthous lesions or skip areas or larger ulcers in the neo‐terminal ileum, ileal inlet, or ileal body with normal mucosa in between, with or without anastomotic line lesions i3: aphthous lesions (regardless of number) with diffusely inflamed mucosa in between in the neo‐terminal ileum, ileal inlet, or ileal body i4: large ulcers with diffuse mucosal inflammation in between or nodules or non‐passable narrowing/stenosis in the neo‐terminal ileum, ileal inlet, or ileal body Specific to postoperative CD Separates lesions from the anastomosis and the ileum, potentially improving prognostic accuracy Considers assessment of all regions created by side‐to‐side or side‐to‐end anastomosis Not validated Does not capture colonic disease activity More comparative evidence needed, given the score's recent development Substantial interobserver variability Moderate interobserver agreement for cutoff point updated RS≥i2a To our knowledge, no published data on intraobserver reliability No data on prognostic performance, but responsiveness of score to therapy demonstrated while not validated Separates lesions from the anastomosis and the ileum Incorporating the assessment of the ileal inlet and ileal body Requires experience in distinguishment of all six anastomotic regionsHammoudi et al. Am J Gastroenterol, 2020REMIND Anastomosis (A): A0: No lesion A1: Ulceration < 50% anastomosis circumference A2: Ulceration > 50% anastomosis circumference A3: Stenosis Neo‐terminal Ileum (I): I0: No lesion I1: < 5 aphthous ulcers I2: > 5 aphthous ulcers or larger ulcers with normal intervening mucosa I3: Diffuse aphthous ileitis with diffusely inflamed mucosa I4: Diffuse inflammation with larger ulcers, nodules and/or narrowing Specific to postoperative CD Separates lesion from the anastomosis and the ileum, potentially improving prognostic accuracy Differentiates the extent of anastomotic lesions Not validated Does not capture colonic disease activity More comparative evidence needed, given the score's recent development Good to substantial interobserver reliability for neo‐terminal ileum Poor to moderate interobserver reliability for anastomosis Fair interobserver agreement for cutoff points ≥ A1 To our knowledge, no published data on intraobserver reliability Modestly explored, but predictive of clinical recurrence Prognostic relevance specifically improved with assessment of ileal activity, associated with worse long‐term outcomes Separates lesion from the anastomosis and the ileumRequires experience in distinguishment of anastomosis Consists of two separate componentsDe Cruz et al. Inflamm Bow Dis, 2022POCER Index Scores 0–4 Combination at the anastomosis of: Ulcer Depth (No, superficial, deep) Circumferential extent (None, < 25%, > 25%) Specific to postoperative CD Practical in use Differentiates the extent of anastomotic lesions Simple to calculate Not validated Only tailored to assessment of the anastomosis Does not capture colonic disease activity More comparative evidence needed, given the score's recent development Moderate interobserver agreement Good intraobserver agreement Poor interobserver agreement for anastomosis Modestly explored, but appears specific for predicting absence of clinical recurrenceNo evaluation of neo‐terminal ileumRequires experience in distinguishment of anastomosis An overview of postoperative endoscopic scores. Segment by segment: Deep ulcerations Superficial ulcerations Surface involved by disease Surface involved by ulcerations Stenosis (ulcerated or not) Exhaustive Validated in luminal CD Captures colonic disease activity Largely used in clinical trials Good to excellent intra‐ and interobserver agreement in luminal CD Substantial intra‐ and interobserver agreement in the postoperative setting Less interobserver agreement for the anastomosis Segment by segment: Size of ulcers Ulcerated surface Affected surface Presence of narrowing Exhaustive Validated in luminal CD Acceptable intra‐ and interobserver agreement in postoperative setting Captures colonic disease activity Largely used in clinical trials Good to excellent intra‐ and interobserver agreement in luminal CD Substantial intra‐ and interobserver agreement in the postoperative setting Less interobserver agreement for the anastomosis Neo‐terminal ileum and anastomosis: i1 = Not more than five anastomotic aphthous lesions in the distal ileum i2 = More than five aphthous lesions with normal mucosa between the lesions, or skip areas of larger lesions or ulcers up to 1 cm confined to ileocecal anastomosis i3 = Diffuse aphthous ileitis with diffusely inflamed mucosa between the multiple aphthae i4 = Diffuse inflammation, with larger lesions: large ulcers, nodules/cobble and/or narrowing/stenosis Specific to postoperative CD anatomy Practical to use Widely used Not validated Does not separate lesion from the anastomosis and the ileum Does not capture colonic disease activity Moderate to substantial interobserver agreement Less interobserver reliability especially when differentiating 5 aphthous ulcers, with normal intervening mucosa in between, in the neo‐terminal ileum (with or without anastomotic lesions) i3 = diffuse aphthous ileitis with diffusely inflamed mucosa i4 = large ulcers with diffuse mucosal inflammation or nodules or stenosis in the neo‐terminal ileum Specific to postoperative CD Separates lesions from the anastomosis and the ileum, potentially improving prognostic accuracy Not validated Does not capture colonic disease activity Substantial interobserver variability Moderate interobserver agreement for cutoff point ≥i2a Good to excellent intraobserver agreement Designed only on end‐to‐end configuration Separates lesions from the anastomosis and the ileum Rivière et al., Clinical Gastroenterology and Hepatology, 2022 Neo‐terminal ileum and anastomosis: i0: No lesions in the neo‐terminal ileum, anastomotic line, ileal inlet, or ileal body i1: < 5 aphthous lesions in the neo‐terminal ileum, ileal inlet, or ileal body with normal mucosa in between i2a: Lesions confined to the ileocecal anastomotic line with or without < 5 aphthous lesions in the neo‐terminal ileum, ileal inlet, or ileal body with normal mucosa in between i2b: ≥ 5 aphthous lesions or skip areas or larger ulcers in the neo‐terminal ileum, ileal inlet, or ileal body with normal mucosa in between, with or without anastomotic line lesions i3: aphthous lesions (regardless of number) with diffusely inflamed mucosa in between in the neo‐terminal ileum, ileal inlet, or ileal body i4: large ulcers with diffuse mucosal inflammation in between or nodules or non‐passable narrowing/stenosis in the neo‐terminal ileum, ileal inlet, or ileal body Specific to postoperative CD Separates lesions from the anastomosis and the ileum, potentially improving prognostic accuracy Considers assessment of all regions created by side‐to‐side or side‐to‐end anastomosis Not validated Does not capture colonic disease activity More comparative evidence needed, given the score's recent development Substantial interobserver variability Moderate interobserver agreement for cutoff point updated RS≥i2a To our knowledge, no published data on intraobserver reliability Separates lesions from the anastomosis and the ileum Incorporating the assessment of the ileal inlet and ileal body Anastomosis (A): A0: No lesion A1: Ulceration < 50% anastomosis circumference A2: Ulceration > 50% anastomosis circumference A3: Stenosis Neo‐terminal Ileum (I): I0: No lesion I1: < 5 aphthous ulcers I2: > 5 aphthous ulcers or larger ulcers with normal intervening mucosa I3: Diffuse aphthous ileitis with diffusely inflamed mucosa I4: Diffuse inflammation with larger ulcers, nodules and/or narrowing Specific to postoperative CD Separates lesion from the anastomosis and the ileum, potentially improving prognostic accuracy Differentiates the extent of anastomotic lesions Not validated Does not capture colonic disease activity More comparative evidence needed, given the score's recent development Good to substantial interobserver reliability for neo‐terminal ileum Poor to moderate interobserver reliability for anastomosis Fair interobserver agreement for cutoff points ≥ A1 To our knowledge, no published data on intraobserver reliability Modestly explored, but predictive of clinical recurrence Prognostic relevance specifically improved with assessment of ileal activity, associated with worse long‐term outcomes Scores 0–4 Combination at the anastomosis of: Ulcer Depth (No, superficial, deep) Circumferential extent (None, < 25%, > 25%) Specific to postoperative CD Practical in use Differentiates the extent of anastomotic lesions Simple to calculate Not validated Only tailored to assessment of the anastomosis Does not capture colonic disease activity More comparative evidence needed, given the score's recent development Moderate interobserver agreement Good intraobserver agreement Poor interobserver agreement for anastomosis Later, the Simple Endoscopic Score—Crohn's Disease (SES‐CD) was developed to provide a simplified but precise measure of endoscopic CD disease activity by quantifying four key lesion characteristics: ulcer size, ulcerated surface, affected surface, and narrowing (Table 1). These features are scored from 0 to 3 across five predefined bowel segments. In luminal CD, the SES‐CD demonstrated good responsiveness to disease activity changes [27]. Owing to its relative simplicity, reproducibility, and ability to reflect global disease burden, it has become one of the most used endoscopic indices in clinical trials and routine practice [26, 28]. Additionally, in 2021, a monocentric work including 207 patients operated for CD (75% with ileal lesions) showed that a SES‐CD > 2 at the first postoperative ileocolonoscopy was significantly associated with subsequent clinical recurrence (p < 0.001). Interestingly, optimal prognostic thresholds differed according to disease distribution: a SES‐CD of 1 was sufficient to predict clinical recurrence in patients with isolated small bowel disease, whereas a higher cutoff of 5 was required in colon‐dominant disease [29]. More recently, a modified SES‐CD score was developed: increased weighting was assigned based on baseline ulcer size, extent of ulceration, presence of non‐passable strictures, and disease located within certain segments of the bowel such as the ileum, as these were demonstrated to have the strongest association with 1‐year endoscopic remission [30]. By emphasizing ileal disease, this approach may be conceptually more adapted with postoperative CD. In a post hoc analysis of the PREVENT trial, Narula et al. assessed the prognostic value of the modified SES‐CD at week 76 for very long‐term clinical recurrence [31]. Both the original and modified SES‐CD performed comparably, with similar area under curve (AUC) to the RS (cutoff: i2) in predicting subsequent clinical recurrence, using a threshold of ≥ 26 for the modified SES‐CD. Additionally, combining components of the SES‐CD and the CDEIS, the novel continuous Endoscopic ulcer Activity Score for Evaluating Crohn's Disease (EASE‐CD) score adds evaluation of ulcer size, depth, and extent. However, it does not assess strictures, and its prognostic value requires further validation [32]. A key advantage of the CDEIS, SES‐CD, and its modified version lie in their ability to capture colonic recurrence, in contrast to ileum‐focused postoperative scores. However, when applied to postoperative CD, several features limit CDEIS and SES‐CD applicability. First, their complexity and the time required for their calculation limit their feasibility. More importantly, the framework of those scores assumes native bowel anatomy and fails to account for postoperative‐specific features, particularly the presence of an anastomosis. The Rutgeerts Score The Original Rutgeerts Score The most recognized endoscopic scoring system dedicated to assessment of POR is the RS [4]. It was designed to grade lesions at the neo‐terminal ileum and ileocecal anastomosis stratifying their severity into five categories based on number, size and distribution of ulcerations, and the extent of mucosal inflammation between ulcerations (Table 1). The RS has been shown to correlate with postoperative outcomes. A significant relationship between lower (i0–i1) and higher (i2–i4) scores in predicting surgical and clinical recurrence was observed in the landmark study and confirmed later on [31, 33, 34]. Consequently, it rapidly became the gold standard for grading the severity of ePOR and is widely used in routine clinical practice, even though it was never prospectively validated [35]. However, several other limitations have emerged. The original RS was developed for end‐to‐end anastomoses, whereas side‐to‐side anastomoses are now commonly performed and other types emerged in CD surgery (Figure 1). As a result, it may underestimate disease activity in regions not present in end‐to‐end configurations [10, 19, 36]. Furthermore, the score does not distinguish between ileal and anastomotic lesions, as an i2 score may reflect either neo‐terminal ileal or anastomotic lesions. Isolated anastomotic lesions are frequently observed and their pathophysiology remains incompletely understood. As they are more common in patients with CD as compared to those who underwent right hemicolectomy for colon cancer and have been associated with an increased long‐term risk of POR, their development may appear to be driven by CD rather than ischemia [37, 38, 39, 40]. Moreover, a prospective study underlined the concept of anastomotic lesions as a distinct postoperative entity, as 40% of patients with such lesions experienced endoscopic progression during follow‐up [37]. However, local ischemia‐related factors may partly contribute to lesion development, a hypothesis supported by their occurrence in patients without CD and observed differences in patterns of anastomotic ulcerations between everted and inverted stapled anastomoses [18, 40]. Indeed, a recent study demonstrated that inverted stapling, in which the bowel edges are folded into the lumen, was associated with more ulcerations at the anastomotic stapled line at the postoperative endoscopy, possibly due to secondary wound healing [18]. Overview of ileocecal anastomotic configurations. Modified Rutgeerts Score (mRS) The lack of distinction between anastomotic and ileal lesions, led to the development of the modified RS (mRS). This score differentiates i2 lesions of the original RS into i2a for lesions limited to the anastomosis, and i2b for > 5 ulcerations surrounded by normal mucosa in the neo‐terminal ileum [41, 42]. Some studies reported no significant differences between the i2a and i2b lesions regarding clinical or surgical POR [43, 44]. Conversely, multiple retrospective and prospective studies highlighted the prognostic importance of distinguishing anastomotic from ileal lesions, demonstrating worse long‐term outcomes in patients with ileal involvement at postoperative endoscopy [6, 45, 46, 47]. Notably, some analyses reported that i2a lesions did not differ significantly from i0–i1 disease, whereas i2b lesions were consistently associated with a higher risk of severe endoscopic postoperative recurrence and re‐resection [6, 46]. Interestingly, in some studies, i1 lesions were even associated with a higher risk of clinical recurrence than i2a, depending on whether inflammation was confined to the anastomosis or involved the neo‐terminal ileum [45]. These observations have raised the questions about whether a ≥ i2b threshold on the mRS is appropriate to define POR and guide treatment adaptation [48]. The Updated Rutgeerts Score A limitation of both the original and modified RS is that their development is based on end‐to‐end anastomoses. To address recurrence at anatomical sites created by other anastomotic configurations, Rivière et al. proposed an updated RS [19]. It incorporates assessment of six separate anatomical areas created by side‐to‐side or side‐to‐end anastomosis, as seen in Figure 2. These include the ileal body, the segment between the anastomosis and the ileal inlet, and the ileal inlet of the neo‐terminal ileum, defined as the region near its entry into the colon in side‐to‐end and side‐to‐side anastomoses. The evaluation of these regions is important, as these might be overlooked with the RS or mRS [19, 48]. Anatomic areas assessed by endoscopic scores. The score might improve postoperative assessment, as it ensures assessment of all regions created during ICR. However, further validation and comparison with existing scoring systems are still needed [49]. Dedicated Postoperative Endoscopic Scores: REMIND And POCER Index The REMIND Score The REMIND score was developed within a French multicenter prospective cohort and separates assessment into two distinct components, namely REMIND‐A and REMIND‐I. REMIND‐A focuses exclusively on anastomotic lesions, evaluating their extent, depth, circumferential involvement, and the presence of associated stenosis. REMIND‐I, in contrast, assesses lesions in the neo‐terminal ileum using a grading system derived from the RS (Table 1) [45]. Data from the original REMIND cohort suggested that ileal involvement is the primary driver of long‐term clinical recurrence. Clinical recurrence‐free survival was significantly shorter in patients with ileal lesions detected at early postoperative endoscopy, regardless of lesion severity (I0 vs. I1: p = 0.0008; I1 vs. I2–4: p = 0.43). Moreover, patients with isolated ileal lesions (A0I1–4) experienced worse long‐term clinical outcomes than those with isolated anastomotic lesions (A1–3I0: p = 0.009). In contrast, isolated anastomotic lesions were linked to anastomotic stenotic complications. A recent Asian cohort further supported the prognostic relevance of mild ileal lesions using the REMIND score [50]. From a clinical perspective, the REMIND score represents an important conceptual advance by distinguishing lesions that likely have different pathophysiological and prognostic meanings. Its role in routine clinical practice remains, however, to be fully defined. The POCER Index A post hoc analysis of the POCER‐trial evaluated the association of the subsequent lesions with endoscopic recurrence: neo‐terminal ileum lesions, anastomotic ulcer depth, number of ulcers, ulcer size, circumferential extent of ulceration, and the presence of stenosis. Among these variables, the combination of ulcer depth and circumferential extent strictly at the anastomosis was independently associated with endoscopic recurrence at 18 months (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.03–2.50; p = 0.035) [51]. Interestingly, ileal lesions alone were not independently associated with recurrence. The main strength of the POCER index lies in its simplicity, facilitating its use in clinical trials and routine practice. However, although it incorporates lesion location, its strong focus on anastomotic findings may not adequately distinguish inflammatory recurrence from postoperative changes related to surgical healing or mechanical stress. Furthermore, the prognostic performance of the POCER index outside the original trial setting has been only modestly explored. Only in a recent Italian multicenter study, a POCER index < 1 showed a specificity of 100% for predicting the absence of clinical recurrence at the 6‐month endoscopic evaluation [52]. Interestingly, the combination of the index with the RS was shown to outperform each of them with a good compromise between sensitivity and specificity. Why Reproducibility Remains a Critical Limitation of Postoperative Endoscopic Indices Depending on the choice of postoperative endoscopic index and the selected threshold, reported recurrence rates may vary substantially. This directly affects clinical trial design, sample size estimation, and the perceived efficacy of preventive therapies. More broadly, the lack of standardized definitions and assessment frameworks complicates the interpretation and implementation of guideline recommendations and contributes to heterogeneous real‐world practices. Consistently, current guidelines do not specifically address postoperative CD recurrence and instead recommend applying endpoints defined for luminal disease [24, 53]. Standardization depends on reproducibility, relying not only on score simplicity, but also on the clarity of assessed lesions. For global scores, while the CDEIS demonstrates good interobserver agreement in luminal CD, its performance appears weaker when applied to postoperative recurrence. Conversely, several studies have reported acceptable intra‐ and interobserver agreement for the SES‐CD in the postoperative setting [26, 54]. A study from the French GETAID group involving 13 expert endoscopists demonstrated only moderate interobserver agreement for the RS, particularly when differentiating